Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.

European journal of cancer (Oxford, England : 1990) - 1 May 2017

Farag Sheima, Somaiah Neeta, Choi Haesun, Heeres Birthe, Wang Wei-Lien, van Boven Hester, Nederlof Petra, Benjamin Robert, van der Graaf Winette, Grunhagen Dirk, Boonstra Pieter A, Reyners Anna K L, Gelderblom Hans, Steeghs Neeltje

Abstract excerpt

PURPOSE: Patients, platelet-derived growth factor receptor alpha (PDGFRA) D842V-mutated gastrointestinal stromal tumours (GISTs) are known for their insensitivity to imatinib. However, in clinical practice responses have been observed in some patients. We describe the natural history and treatment outcomes in a cohort of PDGFRA exon 18 mutated GIST patients. PATIENTS AND METHODS: A retrospective cohort study was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Esophageal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Neoadjuvant Therapy

Share to Netherlands

Share to Palliative Care

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 28284172
DOI: 10.1016/j.ejca.2017.02.007

Genes

PDGFRA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.PMID 28284172Read ↗

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.Semantic proximity Read ↗

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.Semantic proximity Read ↗

The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)Semantic proximity Read ↗

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.Semantic proximity Read ↗

Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.Semantic proximity Read ↗

Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.Semantic proximity Read ↗

Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.Semantic proximity Read ↗

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy.Semantic proximity Read ↗

Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GISTSemantic proximity Read ↗

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.Semantic proximity Read ↗

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world dataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.